品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

MedKoo Biosciences/Aminolevulinic Acid HCl/100054/25g

价格
¥11000.00
货号:100054-25g
浏览量:49
品牌:MedKoo
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Aminolevulinicacid,alsoknownasALA,isatopicallyadmiNISTeredmetabolicprecursorofprotoporphyrinIX.Aftertopicaladministration,aminolevulinicacid(ALA)isconvertedtoprotoporphyrinIX(PpIX)whichisaphotosensitizer.WhentheproperwavelengthoflightactivatesprotoporphyrinIX,singletoxygenisproduced,resultinginalocalcytotoxiceffect.In1999,FDAapprovedthisdrugforforactinickeratosis.

MedKooCat#:100054
Name:AminolevulinicAcidHCl
CAS#:5451-09-2(HCl)
ChemicalFormula:C5H10ClNO3
ExactMass:
MolecularWeight:167.59
ElementalAnalysis:C,35.83;H,6.01;Cl,21.15;N,8.36;O,28.64


RelatedCAS#:5451-09-2(hydrochloride) 106-60-5(freeform) 

Synonym:5-ALA;ALA;dALA;ALAor5-ala;5-aminolevulinicacid;aminolevulinicacid;USbrandname:Levulan.

IUPAC/ChemicalName:5-amino-4-oxopentanoicacidhydrochloride

InChiKey:ZLHFONARZHCSET-UHFFFAOYSA-N

InChiCode:InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H

SMILESCode:O=C(O)CCC(CN)=O.[H]Cl


TechnicalData

Appearance:
Whitetooff-whitesolidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

CertificateofAnalysis:
ViewCoA:currentbatch,Lot#TZC61205

QCData:
ViewQCdata:currentbatch,Lot#TZC61205

SafetyDataSheet(MSDS):
ViewMaterialSafetyDataSheet(MSDS)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
Solubleinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
Thisdrugmaybeformulatedinwater

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation


References

1:InoueK.5-Aminolevulinicacid-mediatedphotodynamictherapyforbladdercancer.IntJUrol.2017Feb;24(2):97-101.doi:10.1111/iju.13291.Review.PubMedPMID:28191719.

2:KumarN,WarrenCB.PhotodynamicTherapyforDermatologicConditionsinthePediatricPopulation:ALiteratureReview.PhotodermatolPhotoimmunolPhotomed.2017Jan28.doi:10.1111/phpp.12296.[Epubaheadofprint]Review.PubMedPMID:28130791.

3:HuangZ,ShiS,QiuH,LiD,ZouJ,HuS.Fluorescence-guidedresectionofbraintumor:reviewofthesignificanceofintraoperativequantificationofprotoporphyrinIXfluorescence.Neurophotonics.2017Jan;4(1):011011.doi:10.1117/1.NPh.4.1.011011.Review.PubMedPMID:28097209;PubMedCentralPMCID:PMC5227178.

4:ZhangY,AvalosJL.TrADItionalandnoveltoolstoprobethemitochondrialmetabolisminhealthanddisease.WileyInterdiscipRevSystBiolMed.2017Jan9.doi:10.1002/wsbm.1373.[Epubaheadofprint]Review.PubMedPMID:28067471.

5:LaneAM,McKayJT,BonkovskyHL.Advancesinthemanagementoferythropoieticprotoporphyria-roleofafamelanotide.ApplClinGenet.2016Dec12;9:179-189.doi:10.2147/TACG.S122030.Review.PubMedPMID:28003770;PubMedCentralPMCID:PMC5161401.

6:Ameluzforactinickeratoses.MedLettDrugsTher.2016Dec5;58(1509):155-156.Review.PubMedPMID:27906150.

7:XueJ,LiuC,LiuY.Photodynamictherapyasanalternativetreatmentforrelapsedorrefractorymycosisfungoides:asystemicreview.PhotodiagnosisPhotodynTher.2016Nov22.pii:S1572-1000(16)30184-3.doi:10.1016/j.pdpdt.2016.11.010.[Epubaheadofprint]Review.PubMedPMID:27888162.

8:SendersJT,MuskensIS,SchnoorR,KarhadeAV,CoteDJ,SmithTR,BroekmanML.Agentsforfluorescence-guidedgliomasurgery:asystematicreviewofpreclinicalandclinicalresults.ActaNeurochir(Wien).2017Jan;159(1):151-167.doi:10.1007/s00701-016-3028-5.Review.PubMedPMID:27878374;PubMedCentralPMCID:PMC5177668.

9:BelykhE,MartirosyanNL,YagmurluK,MillerEJ,EschbacherJM,IzadyyazdanabadiM,BardonovaLA,ByvaltsevVA,NakajiP,PreulMC.IntraoperativeFluorescenceImagingforPersonalizedBrainTumorResection:CurrentStateandFutureDirections.FrontSurg.2016Oct17;3:55.Review.PubMedPMID:27800481;PubMedCentralPMCID:PMC5066076.

10:AroraS,YoungS,KodaliS,SingalAK.Hepaticporphyria:Anarrativereview.IndianJGastroenterol.2016Nov;35(6):405-418.Review.PubMedPMID:27796941.

11:CohenDK,LeePK.PhotodynamicTherapyforNon-MelanomaSkinCancers.Cancers(Basel).2016Oct4;8(10).pii:E90.Review.PubMedPMID:27782043;PubMedCentralPMCID:PMC5082380.

12:ChouR,SelphS,BuckleyDI,FuR,GriffinJC,GrusingS,GoreJL.ComparativeEffectivenessofFluorescentVersusWhiteLightCystoscopyforInitialDiagnosisorSurveillanceofBladderCanceronClinicalOutcomes:SystematicReviewandMeta-Analysis.JUrol.2016Oct22.pii:S0022-5347(16)31585-3.doi:10.1016/j.juro.2016.10.061.[Epubaheadofprint]Review.PubMedPMID:27780784.

13:GirottiAW,FaheyJM,KorytowskiW.MultipleMeansbyWhichNitricOxidecanAntagonizePhotodynamicTherapy.CurrMedChem.2016;23(24):2754-2769.Review.PubMedPMID:27776475.

14:Fonda-PascualP,Moreno-ArronesOM,Alegre-SanchezA,Saceda-CorraloD,Buendia-CastañoD,Pindado-OrtegaC,Fernandez-GonzalezP,Velazquez-KennedyK,Calvo-SánchezMI,Harto-CastañoA,Perez-GarciaB,BagazgoitiaL,Vaño-GalvanS,EspadaJ,Jaen-OlasoloP.InsituproductionofROSintheskinbyphotodynamictherapyasapowerfultoolinclinicaldermatology.Methods.2016Oct15;109:190-202.doi:10.1016/j.ymeth.2016.07.008.Review.PubMedPMID:27422482.

15:HalaniSH,AdamsonDC.Clinicalutilityof5-aminolevulinicacidHCltobettervisualizeandmorecompletelyremovegliomas.OncoTargetsTher.2016Sep12;9:5629-42.doi:10.2147/OTT.S97030.Review.PubMedPMID:27672334;PubMedCentralPMCID:PMC5026178.

16:BarbaricJ,AbbottR,PosadzkiP,CarM,GunnLH,LaytonAM,MajeedA,CarJ.Lighttherapiesforacne.CochraneDatabaseSystRev.2016Sep27;9:CD007917.[Epubaheadofprint]Review.PubMedPMID:27670126.

17:AndrewH,GossedgeG,CroftJ,CorriganN,BrownJM,WestN,QuirkeP,TolanD,CahillR,JayneDG.NextGenerationintraoperativeLymphnodestagingforStratifiedcoloncancersurgery(GLiSten):amulticentre,multinationalfeasibilitystudyoffluorescenceinpredictinglymphnode-positivedisease.Southampton(UK):NIHRJournalsLibrary;2016Aug.PubMedPMID:27536753.

18:MarandaEL,NguyenAH,LimVM,ShahVV,JimenezJJ.ErythroplasiaofQueyrattreatedbylaserandlightmodalities:asystematicreview.LasersMedSci.2016Dec;31(9):1971-1976.Review.PubMedPMID:27324019.

19:FujitaAK,RodriguesPG,RequenaMB,EscobarA,daRochaRW,NardiAB,KurachiC,deMenezesPF,BagnatoVS.FluorescenceevaluationsforporphyrinformationduringtopicalPDTusingALAandmethyl-ALAmixturesinpigskinmodels.PhotodiagnosisPhotodynTher.2016Sep;15:236-44.doi:10.1016/j.pdpdt.2016.05.008.Review.PubMedPMID:27288253.

20:KampMA,KrauseMolleZ,Munoz-BendixC,RappM,SabelM,SteigerHJ,CorneliusJF.Variousshadesofred-asystematicanalysisofqualitativeestimationofALA-derivedfluorescenceinneurosurgery.NeurosurgRev.2016May25.[Epubaheadofprint]Review.PubMedPMID:27225452.

我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是:建成全球最大的小分子抗癌药库 ,品种最多最全、质量最好最可靠。美帝药库的宗旨是:客户第一;质量第一;信誉第一;创新第一。